Heui-Soo Moon1, Soo-Jin Cho2, Byung-Kun Kim3, Mi Ji Lee4, Pil-Wook Chung1, Jong-Hee Sohn5, Soo-Kyoung Kim6, Yun-Ju Choi7, Tae-Jin Song8, Jae-Moon Kim9, Jeong Wook Park10, Kwang-Yeol Park11, Jae-Myun Chung12, Jin-Young Ahn13, Byung-Su Kim14, Kyungmi Oh15, Kwang-Soo Lee16, Chin-Sang Chung4, Min Kyung Chu17. 1. 1 Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. 2 Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea. 3. 3 Department of Neurology, Eulji University School of Medicine, Seoul, Korea. 4. 4 Department of Neurology, Neuroscience Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 5. 5 Department of Neurology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea. 6. 6 Department of Neurology, Gyeongsang National University School of Medicine, Jinju, Korea. 7. 7 Department of Neurology, Presbyterian Medical Center, Jeonju, Korea. 8. 8 Department of Neurology, Ewha Womans University School of Medicine, Seoul, Korea. 9. 9 Department of Neurology, Chungnam National University College of Medicine, Daejeon, Korea. 10. 10 Department of Neurology, Uijeongbu St. Mary's Hospital, The Catholic University of Korea College of Medicine, Uijeongbu, Korea. 11. 11 Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. 12. 12 Department of Neurology, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea. 13. 13 Department of Neurology, Seoul Medical Center, Seoul, Korea. 14. 14 Department of Neurology, Bundang Jesaeng General Hospital, Daejin Medical Center, Seongnam, Korea. 15. 15 Department of Neurology, Korea University College of Medicine, Seoul, Korea. 16. 16 Department of Neurology, Seoul St. Mary's Hospital, Catholic University of Korea College of Medicine, Seoul, Korea. 17. 17 Department of Neurology, Severance Hospital, Yonsei University School of Medicine, Seoul, Korea.
Abstract
BACKGROUND: *These authors are shared first authors. The recently published third edition of the International Classification of Headache Disorders (ICHD-3) revised the criteria for accompanying symptoms of cluster headache (CH) and the remission period of chronic cluster headache (CCH). This study aimed at testing the validity of the ICHD-3 criteria for CH by using data from the Korean Cluster Headache Registry. METHODS: Consecutive patients with CH and probable cluster headache (PCH) were prospectively recruited from 15 hospitals. We analysed the validity of the revised ICHD-3 criteria for CH against the beta version of the third edition of the ICHD (ICHD-3β). RESULTS: In total, 193 patients were enrolled: 140 (72.5%), 5 (2.6%) and 22 (11.4%) had episodic cluster headache (ECH), CCH, and PCH, respectively. The remaining 26 (13.5%) had CH with undetermined remission periods. One patient with ECH and one with PCH had only forehead and facial flushing and were diagnosed with PCH and non-cluster headache, respectively, according to the ICHD-3. Four participants with ECH according to the ICHD-3β had remission periods of > 1 month and between 1 and 3 months and were newly diagnosed with CCH according to the ICHD-3. CONCLUSION: The change from ICHD-3β to ICHD-3 resulted in few differences in the diagnoses of CH and PCH.
BACKGROUND: *These authors are shared first authors. The recently published third edition of the International Classification of Headache Disorders (ICHD-3) revised the criteria for accompanying symptoms of cluster headache (CH) and the remission period of chronic cluster headache (CCH). This study aimed at testing the validity of the ICHD-3 criteria for CH by using data from the Korean Cluster Headache Registry. METHODS: Consecutive patients with CH and probable cluster headache (PCH) were prospectively recruited from 15 hospitals. We analysed the validity of the revised ICHD-3 criteria for CH against the beta version of the third edition of the ICHD (ICHD-3β). RESULTS: In total, 193 patients were enrolled: 140 (72.5%), 5 (2.6%) and 22 (11.4%) had episodic cluster headache (ECH), CCH, and PCH, respectively. The remaining 26 (13.5%) had CH with undetermined remission periods. One patient with ECH and one with PCH had only forehead and facial flushing and were diagnosed with PCH and non-cluster headache, respectively, according to the ICHD-3. Four participants with ECH according to the ICHD-3β had remission periods of > 1 month and between 1 and 3 months and were newly diagnosed with CCH according to the ICHD-3. CONCLUSION: The change from ICHD-3β to ICHD-3 resulted in few differences in the diagnoses of CH and PCH.
Authors: Randika Parakramaweera; Randolph W Evans; Larry I Schor; Stuart M Pearson; Rebecca Martinez; Jacob S Cammarata; Amisha J Amin; Seung-Hee Yoo; Wei Zhang; Yuanqing Yan; Mark J Burish Journal: Cephalalgia Date: 2021-06-20 Impact factor: 6.292